When the product description keeps changing
Compare the words in the offer with the words in the written proposal. Does the service name the ingredient and form consistently? Can it say whether it proposes an approved product or a compound? Keep the answers together rather than trying to resolve a mismatch from memory.
As checked November 3, 2026, FDA identifies describing a compounded medicine as FDA-approved or as an approved generic as false or misleading. A compound’s lack of approval is distinct from whether a particular compounding proposal meets applicable rules.
If approval is claimed, ask for the product’s approval record. If compounding is proposed, ask for the patient-specific reason and the pharmacy name. You are seeking a clear description of the offer, not a general assurance about the service.
When a research label is presented as treatment
FDA has said that promises about effects on people show a product is meant to be used as a drug, even if its label describes research. That FDA position was checked November 3, 2026. Research labels do not cancel those claims.
Ask whether a licensed professional will assess your concern and, if appropriate, prescribe a named medicine for you. A research description does not answer that care question. Keep any promotional page you want to discuss so the named professional can address the actual words rather than a general description of the internet.
A valid prescription must come before dispensing a prescription medicine under the federal provision checked November 3, 2026. FDA’s pharmacy checks also flag sites that dispense without one.
An intake form alone does not tell you what happens afterward. Find out who reads the form, how the assessment responds to your replies and whether the decision-maker is reachable. If the reply is unclear, return to the assessment rather than moving straight to payment.
Check the pharmacy and the care arrangements
A traceable pharmacy
FDA has documented compounded semaglutide and tirzepatide with false pharmacy information, including nonexistent pharmacy names. That account was checked November 3, 2026.
Ask for the actual dispensing pharmacy and the record that matches it. Keep the business name distinct from the consultation platform or clinic name. If a label later shows a different name, ask for an explanation rather than assuming the difference is routine.
FDA’s pharmacy checklist calls for state licensure and a valid prescription, with a licensed pharmacist to answer questions. FDA also cautions that convincing storefronts can be fake; this checklist was checked September 17, 2026.
Use the public record and the answer from the pharmacy together. Ask who can explain the product and its written information. A badge, an attractive website or a familiar clinic name does not answer who made the proposed medicine.
Questions before payment
FDA lists unusually deep discounts among warning signs, but a low price by itself does not establish a problem. That limited signal was checked September 17, 2026 and needs the rest of the pharmacy checks beside it.
Ask for the fee terms and the care plan before deciding. Ask who handles later questions and how reviews are arranged. Find out what the visit costs if the result is no prescription. Save the answers so the comparison remains about the whole proposal.
If you cannot obtain an exact product name, a responsible person or a usable explanation, keep that item unresolved. You can discuss the offer with a licensed health professional you already know. The question page turns these gaps into direct requests for information.